19:59 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

Merck KGaA reports response data for tepotinib in c-MET mutant NSCLC

Merck KGaA (Xetra:MRK) said 500 mg once-daily tepotinib (MSC2167119J) led to a partial response rate of 42.9% and a stable disease rate of 21.4% based on independent assessment in the first 28 patients in the...
19:18 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

Merck KGaA reports Phase I response data for M7824 in HPV-associated cancer

Merck KGaA (Xetra:MRK) reported response data at the American Society of Clinical Oncology (ASCO) meeting in Chicago from a Phase I trial of M7824 to treat advanced or metastatic HPV-associated malignancies, including cervical, anal and...
19:16 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

Merck KGaA reports Phase I response data for M7824 in NSCLC

Merck KGaA (Xetra:MRK) reported response data at the American Society of Clinical Oncology (ASCO) meeting in Chicago from a cohort of patients with advanced non-small cell lung cancer in a Phase I trial of M7824. In...
19:13 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

Merck KGaA's tepotinib meets in two Phase Ib/II trials for advanced HCC

Merck KGaA (Xetra:MRK) said once-daily oral tepotinib (MSC2156119J) as first- and second-line treatment each met the primary endpoints in the Phase II portions of two open-label Phase Ib/II trials to treat advanced c-Met receptor tyrosine...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate of...
00:06 , Jun 28, 2018 |  BC Extra  |  Company News

Management tracks: Arrakis, Astellas

Arrakis Therapeutics Inc. (Waltham, Mass.) founder and CSO Russ Petter is transitioning to Jennifer. The news was announced in a blog post by Chairman and CEO Michael Gilman. "The support for this transition at Arrakis,...
17:58 , Jun 22, 2018 |  BC Week In Review  |  Clinical News

FDA places hold on upcoming Phase I for point-of-care CAR Ts

FDA placed a clinical hold on an upcoming Phase I trial sponsored by Ziopharm Oncology Inc. (NASDAQ:ZIOP), which would be the first for its third-generation, point-of-care CAR T cells that require two days for manufacturing....
23:50 , Jun 18, 2018 |  BC Extra  |  Clinical News

Hold for upcoming point-of-care CAR T trial sinks Ziopharm shares

FDA placed a clinical hold on an upcoming Phase I trial sponsored by Ziopharm Oncology Inc. (NASDAQ:ZIOP), which would be the first for its third-generation, point-of-care CAR T cells that require two days for manufacturing....
00:25 , Jun 16, 2018 |  BioCentury  |  Product Development

NSCLC disrupted

This year’s ASCO made clear that PD-1 inhibitors have supplanted chemotherapy as standard of care in first-line metastatic NSCLC. The unanticipated consequence is the knock-on effects for companies with studies under way in both first-...
00:18 , Jun 16, 2018 |  BioCentury  |  Finance

Rejuvenating aging

Anti-aging company Juvenescence Ltd. is hoping to bring a total of 10 candidates from its portfolio companies and academic partnerships into the clinic over the next two years with its recent $50 million series A...